Sector News

Actelion re-enters talks with J&J, sidelining Sanofi

December 22, 2016
Life sciences

Swiss biotech company Actelion has turned back to prospective bidder Johnson & Johnson for exclusive talks about a “strategic transaction”, in an about-turn that appears to sideline rival suitor Sanofi.

Actelion said in a brief statement on Wednesday it was in exclusive negotiations with the U.S. healthcare giant but that there could be “no assurance any transaction will result from these discussions”, declining to comment further.

J&J confirmed the talks in a separate statement.

The announcement could dash the hopes of French drugmaker Sanofi, which sources have said has been circling Actelion after J&J a little over a week ago said it had ended discussions with Actelion.

Sanofi has been trying to broaden its drug line-up as its key diabetes business comes under pressure.

The French company has signaled it remained keen to make a takeover deal after being trumped in August by Pfizer’s (PFE.N) $14 billion bid for U.S. cancer drug company Medivation.

Sanofi declined to comment on Wednesday.

Actelion had a market value of 23.2 billion Swiss francs ($22.6 billion) at Wednesday’s closing price of 215 Swiss francs in Switzerland.

U.S. shares in Actelion rose 11 percent after the announcement. J&J shares were down 0.3 percent at 1815 GMT.

Actelion had told J&J before initial talks collapsed last week that it was confident it could attract an offer significantly higher than the approximately 250 Swiss francs per share the U.S. company had offered, one person familiar with the matter said.

There were also disagreements about the proposed deal’s structure, the person added at the time.

Actelion co-founder and Chief Executive Jean-Paul Clozel has fended off previous takeover attempts, including a reported takeover approach by Shire (SHP.L) last year and an activist campaign in 2011 by U.S. hedge fund Elliott Advisors.

Acquiring the Swiss biotech firm would boost J&J’s drug pipeline and diversify its prospects. J&J’s biggest product, the arthritis drug Remicade, faces cheaper competition from Pfizer (PFE.N).

($1 = 1.0255 Swiss francs)

By John Revill and Ludwig Burger

Source: Reuters

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach